Evidence map›Paper›PMID 40087567›Full record

ArticleBMC bioinformatics2025

A clinical knowledge graph-based framework to prioritize candidate genes for facilitating diagnosis of Mendelian diseases and rare genetic conditions.

Rohan Gnanaolivu, Gavin Oliver, Garrett Jenkinson, Emily Blake, Wenan Chen, Nicholas Chia, Eric W Klee, Chen Wang

Abstract read
In one paragraph

Article in BMC bioinformatics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Rohan GnanaolivuDepartment of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, 55905, USA.
Gavin OliverDepartment of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, 55905, USA.
Garrett JenkinsonDepartment of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, 55905, USA.
Emily BlakeDepartment of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, 55905, USA.
Wenan ChenDepartment of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, 55905, USA.
Nicholas ChiaDepartment of Surgery, Mayo Clinic, Rochester, MN, 55905, USA.
Eric W KleeDepartment of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, 55905, USA.
Chen WangDepartment of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, 55905, USA. wang.chen@mayo.edu.

Funding

Wellcome Trust
6 · The paper itself

Abstract

backgroundDiagnosing Mendelian and rare genetic conditions requires identifying phenotype-associated genetic findings and prioritizing likely disease-causing genes. This task is labor-intensive for molecular and clinical geneticists, who must review extensive literature and databases to link patient phenotypes with causal genotypes. The challenge is further complicated by the large number of genetic variants detected through next-generation sequencing, which impacts both diagnosis timelines and patient care strategies. To address this, in silico methods that prioritize causal genes based on patient-derived phenotypes offer an effective solution, reducing the time involved in diagnostic case reviews and enhancing the efficiency of clinical diagnosis.

resultsWe developed the phenotype prioritization and analysis for rare diseases (PPAR) to rank genes based on human phenotype ontology (HPO) terms, with the specific goal of aiding the interpretation of genetic testing for Mendelian and rare diseases. PPAR leverages embeddings from a knowledge graph and incorporates knowledge from connections between genes, HPO terms, and gene ontology annotations. When applied on a clinical rare disease cohort and the publicly available deciphering developmental disorders (DDD) dataset. PPAR ranked the causal gene in the top 10 for 27% of cases in the clinical cohort and for 85% of cases in the DDD dataset, outperforming other established HPO-based methods.

conclusionOur findings demonstrate that PPAR, a method developed from the clinical knowledge graph, effectively ranks causal genes based on patient-derived HPO terms in rare and Mendelian disease contexts. PPAR has shown superior performance compared to other well-established HPO-only methods and provides an efficient, accessible solution for clinical geneticists. The Python-based tool is publicly available at https://github.com/dimi-lab/PPAR , offering a user-friendly platform for gene prioritization.

Indexed as

Computational BiologyGenetic Diseases, InbornRare DiseasesDatabases, GeneticGene OntologyHumansPhenotypeGene prioritizationHuman Phenotype OntologyKnowledge graphRare disease

Identifiers

PMID40087567
PMCPMC11908102

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.